Answers are grounded in this paper and cite their sources.
There is a growing demand for new diabetes drugs with fewer side effects to replace current medications known for their adverse effects. Inhibition of α-glucosidase responsible for postprandial hyperglycemia among diabetes patients is a promising strategy for managing the disease. This study aims to explore and identify novel bioactive metabolites with anti-diabetes potential from Alternaria alternata BRN05, an endophytic fungus isolated from a well-known medicinal plant Swietenia macrophylla King. Ethyl acetate extracts of Alternaria alternata BRN05 grown in full-strength (EFS) and quarter-strength (EQS) media, respectively were evaluated for their α-glucosidase inhibitory activities. Based on IC 50 values, EQS exhibited significantly greater inhibitory activity (0.01482 ± 1.809 mg/mL) as compared to EFS (1.16 ± 0.173 mg/mL) as well as acarbose control (0.494 ± 0.009 mg/mL). EFS and EQS were subjected to metabolic profiling using Ultra-High-Performance Liquid Chromatography - Electrospray Ionization - Quadrupole Time-of-Flight Mass Spectrometry (UHPLC-ESI-QTOF-MS). A total of nineteen metabolites from EFS and twenty from EQS were tentatively identified based on MS/MS fragmentation. Molecular docking analysis revealed that twelve among these exhibited greater binding energies than that of acarbose (-6.6 kcal/mol). Molecular Dynamics (MD) simulations of 3’,4’,7-trihydroxyisoflavanone (THF) and alternariol 9-methyl ether (AME) from EQS, exhibiting high binding energies (-7.5 and -7 kcal/mol, respectively), were performed to investigate their interactions with human intestinal α-glucosidase. Results suggest THF possesses strong inhibitory potential, making it a promising candidate for diabetes management.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: